Volume 18, Number 7—July 2012
Dispatch
Seroconversion to Seasonal Influenza Viruses after A(H1N1)pdm09 Virus Infection, Quebec, Canada
Table A1
A(H1N1)pdm09 virus | Age, y |
Received seasonal vaccine in 2008–09 | A/Quebec/147023/2009; A(H1N1)pdm09 |
A/Brisbane/59/2007 (H1N1) |
A/New Caledonia/99 (H1N1) |
A/Panama/2007/99 (H3N2) |
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mean† | Median (range) | Seroconversion rate† | GMT (95% CI) | Seroconversion rate† | GMT (95% CI) | Seroconversion rate† | GMT (95% CI) | Seroconversion rate | GMT (95% CI) | |||||
Positive, n = 67‡ | 25.7 | 20 (7–61) | 19 (28) | 57 (85) | 69.2 (49.9–95.9) | 8 (12) | 104.7 (73.5–149.1) | 7 (10) | 96.5 (65.5–142.4) | 6 (9) | 285.6 (188.5–432.6) | |||
Negative, n = 55 | 31.2 | 35.5 (8–55) | 13 (24) | 0 | 5.9 (5.2–6.8) | 1 (2) | 41.0 (28.4–59.2) | 0 | 34.4 (22.2–53.3) | 3 (5) | 124.4 (77.5–199.6) |
*Values are no. (%) except as indicated. Seroconversion defined as an acute-phase serum titer of <10 with a convalescent-phase titer of >40 or a significant increase (>4-fold) in antibody titers between acute- and convalescent-phase serum samples. GMT, geometric mean titer;
†p<0.05.
‡A(H1N1)pdm09-positive persons were defined by positive reverse transcription PCR and/or seroconversion by microneutralization assay.
Page created: June 13, 2012
Page updated: June 13, 2012
Page reviewed: June 13, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.